GlaxoSmithKline announced that data have been received from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program. GSK intends to commence global regulatory submissions for its investigational glucagon-like peptide-1 receptor agonist albiglutide for the treatment of type 2 diabetes in early 2013. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication. At the 26-week primary endpoint, albiglutide showed clinically and statistically significant reductions in HbA1c from baseline and superiority versus sitagliptin. At the primary endpoint, weight loss was significantly greater in the albiglutide group than the sitagliptin group.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?